Related Experiment Video
Updated: Jan 7, 2026
A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection
Published on: March 8, 2017
A fast-slow liposome based "orthodox-unexpected interplay" strategy for bacterial otitis media and associated hearing
Huaan Li1, Letian Cao1, Suling Huang1
1Guangdong Provincial Key Laboratory of Pharmaceutical Preparations Research and Evaluation & Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, School of Pharmacy & Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Abstract:
Otitis media (OM), the most common infectious disease affecting the middle ear, is a major cause of hearing loss worldwide. It is primarily caused by bacteria such as Staphylococcus aureus (S. aureus), which invade the tympanum, form dense biofilms, and induce persistent inflammation. Conventional treatments rely on multiple doses of antibiotics, which often lead to drug resistance and ineffectiveness. Here, we introduce a fast-slow liposome platform (lip@Lys/NC) based on an "orthodox-unexpected interplay" principle, integrating bacteriolysis, quorum sensing inhibition, and anti-inflammation for effective biofilm disruption and inflammation reduction. Lip@Lys/NC consists of lysostaphin (Lys, for rapid bacteriolysis) and chitosan nanoparticles loaded with curcumin/tanshinone IIA (CUR/TSIIA, for sustained anti-biofilm and anti-inflammation effects), allowing immediate bacterial killing with prolonged therapeutic effect. In vitro studies demonstrate that lip@Lys/NC exhibits potent antibacterial activity against methicillin-resistant S. aureus (MRSA), disrupts biofilms, inhibits quorum sensing, and decreases pro-inflammatory factors. Notably, this synergistic effect does not induce drug resistance, unlike traditional antibiotics. In guinea pig models of S. aureus/MRSA-induced acute and chronic OM, lip@Lys/NC effectively reduces middle-ear inflammation and dismantles bacterial biofilms. Moreover, it protects cochlear hair cells, reduces inflammatory mediator infiltration into the inner ear, and prevents hearing loss, achieving an efficient "orthodox-unexpected interplay" strategy for OM treatments. This integrated system offers a promising non-antibiotic therapeutic approach for MRSA-associated OM, addressing both pathogen elimination and hearing preservation.
Insights
A novel liposome platform (lip@Lys/NC) effectively treats middle ear infections (Otitis Media) by rapidly killing bacteria and reducing inflammation. This non-antibiotic approach prevents hearing loss and avoids drug resistance.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Infectious Diseases
Background:
- Otitis media (OM) is a common middle ear infection causing hearing loss, often due to Staphylococcus aureus (S. aureus).
- Antibiotic resistance and ineffectiveness are significant challenges in current OM treatments.
- S. aureus forms biofilms and induces inflammation, complicating treatment strategies.
Purpose of the Study:
- To develop a novel fast-slow liposome platform (lip@Lys/NC) for Otitis Media treatment.
- To integrate bacteriolysis, quorum sensing inhibition, and anti-inflammation for effective biofilm disruption.
- To offer a non-antibiotic therapeutic alternative for S. aureus-associated OM, preserving hearing.
Main Methods:
- A liposome platform (lip@Lys/NC) combining lysostaphin (Lys) for rapid lysis and curcumin/tanshinone IIA (CUR/TSIIA) loaded chitosan nanoparticles for sustained effects.
- In vitro testing against methicillin-resistant S. aureus (MRSA), including biofilm disruption and quorum sensing inhibition assays.
- In vivo studies using guinea pig models of S. aureus/MRSA-induced acute and chronic OM, evaluating inflammation, biofilm reduction, and hearing preservation.
Main Results:
- lip@Lys/NC demonstrated potent antibacterial activity against MRSA and effectively disrupted biofilms in vitro.
- The platform inhibited quorum sensing and reduced pro-inflammatory factors without inducing antibiotic resistance.
- In vivo, lip@Lys/NC significantly reduced middle ear inflammation, dismantled biofilms, protected cochlear hair cells, and prevented hearing loss.
Conclusions:
- The lip@Lys/NC platform offers a synergistic, non-antibiotic approach for treating S. aureus/MRSA-induced Otitis Media.
- This strategy effectively targets bacterial biofilms and inflammation while preserving hearing.
- The fast-slow liposome system presents a promising therapeutic avenue for Otitis Media, overcoming antibiotic resistance issues.
